Dicerna

DRNA NASDAQ
15.52
-0.26
-1.65%
Opening 10:47 07/19 EDT
Open
15.75
Prev Close
15.78
High
15.80
Low
15.46
Volume
49.56K
Avg Vol (3M)
400.31K
52 Week High
17.98
52 Week Low
9.31
% Turnover
0.07%
Market Cap
1.06B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Dicerna DRNA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
MORE >

Recently

Name
Price
%Change